Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the sale, the insider now directly owns 134,021 shares in the company, valued at approximately $2,189,903.14. The trade was a 6.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock traded up $0.08 during mid-day trading on Friday, reaching $14.59. 620,346 shares of the company were exchanged, compared to its average volume of 548,232. The firm's 50-day simple moving average is $16.48 and its two-hundred day simple moving average is $16.44. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The firm has a market cap of $1.92 billion, a PE ratio of -9.54 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating on the stock. Morgan Stanley restated an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $26.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in Centessa Pharmaceuticals by 88.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company's stock worth $4,237,000 after purchasing an additional 124,075 shares during the period. FMR LLC boosted its stake in shares of Centessa Pharmaceuticals by 4.6% in the third quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after buying an additional 129,300 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Centessa Pharmaceuticals during the third quarter worth $4,951,000. Suvretta Capital Management LLC purchased a new position in Centessa Pharmaceuticals in the third quarter worth $1,119,000. Finally, Walleye Capital LLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at $187,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.